piperidines and bedaquiline

piperidines has been researched along with bedaquiline* in 5 studies

Other Studies

5 other study(ies) available for piperidines and bedaquiline

ArticleYear
Study of the bioenergetics to identify the novel pathways as a drug target against Mycobacterium tuberculosis using Petri net.
    Bio Systems, 2021, Volume: 209

    Tuberculosis is one of the life-threatening diseases globally, caused by the bacteria Mycobacterium tuberculosis. In order to control this epidemic globally, there is an urgent need to discover new drugs with novel mechanism of action that can help in shortening the duration of treatment for both drug resistant and drug sensitive tuberculosis. Mycobacterium essentially depends on oxidative phosphorylation for its growth and establishment of pathogenesis. This pathway is unique in Mycobacterium tuberculosis as compared to host due to the differences in some of the enzyme complexes carrying electron transfer. Hence, it serves as an important drug target area. The uncouplers which inhibit adenosine triphosphate synthesis, could play a vital role in serving as antimycobacterial agents and thus could help in eradicating this deadly disease. In this article, the bioenergetics of Mycobacterium tuberculosis are studied with and without uncouplers using Petri net. Petri net is among the most widely used mathematical and computational tools to model and study the complex biochemical networks. We first represented the bioenergetic pathway as a Petri net which is then validated and analyzed using invariant analysis techniques of Petri net. The valid mathematical models presented here are capable to explain the molecular mechanism of uncouplers and the processes occurring within the electron transport chain of Mycobacterium tuberculosis. The results explained the net behavior in agreement with the biological results and also suggested some possible processes and pathways to be studied as a drug target for developing antimycobacterials.

    Topics: Algorithms; Antitubercular Agents; Computational Biology; Diarylquinolines; Drug Design; Drug Resistance, Bacterial; Electron Transport; Energy Metabolism; Humans; Imidazoles; Metabolic Networks and Pathways; Models, Theoretical; Mycobacterium tuberculosis; Oxidative Phosphorylation; Piperidines; Pyridines; Tuberculosis

2021
Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses.
    PLoS neglected tropical diseases, 2020, Volume: 14, Issue:8

    Buruli ulcer (BU), caused by Mycobacterium ulcerans, is currently treated with a daily combination of rifampin and either injectable streptomycin or oral clarithromycin. An intermittent oral regimen would facilitate treatment supervision. We first evaluated the bactericidal activity of newer antimicrobials against M. ulcerans using a BU animal model. The imidazopyridine amine telacebec (Q203) exhibited high bactericidal activity whereas tedizolid (an oxazolidinone closely related to linezolid), selamectin and ivermectin (two avermectine compounds) and the benzothiazinone PBTZ169 were not active. Consequently, telacebec was evaluated for its bactericidal and sterilizing activities in combined intermittent regimens. Telacebec given twice a week in combination with a long-half-life compound, either rifapentine or bedaquiline, sterilized mouse footpads in 8 weeks, i.e. after a total of only 16 doses, and prevented relapse during a period of 20 weeks after the end of treatment. These results are very promising for future intermittent oral regimens which would greatly simplify BU treatment in the field.

    Topics: Animals; Antitubercular Agents; Buruli Ulcer; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Female; Imidazoles; Mice; Mice, Inbred BALB C; Mycobacterium ulcerans; Oxazolidinones; Piperidines; Pyridines; Rifampin; Tetrazoles

2020
Active pulmonary targeting against tuberculosis (TB) via triple-encapsulation of Q203, bedaquiline and superparamagnetic iron oxides (SPIOs) in nanoparticle aggregates.
    Drug delivery, 2019, Volume: 26, Issue:1

    Tuberculosis (TB) has gained attention over the past few decades by becoming one of the top ten leading causes of death worldwide. This infectious disease of the lungs is orally treated with a medicinal armamentarium. However, this route of administration passes through the body's first-pass metabolism which reduces the drugs' bioavailability and toxicates the liver and kidneys. Inhalation therapy represents an alternative to the oral route, but low deposition efficiencies of delivery devices such as nebulizers and dry powder inhalers render it challenging as a favorable therapy. It was hypothesized that by encapsulating two potent TB-agents, i.e. Q203 and bedaquiline, that inhibit the oxidative phosphorylation of the bacteria together with a magnetic targeting component, superparamagnetic iron oxides, into a poly (D, L-lactide-co-glycolide) (PDLG) carrier using a single emulsion technique, the treatment of TB can be a better therapeutic alternative. This simple fabrication method achieved a homogenous distribution of 500 nm particles with a magnetic saturation of 28 emu/g. Such particles were shown to be magnetically susceptible in an

    Topics: A549 Cells; Administration, Inhalation; Antitubercular Agents; Biological Availability; Cell Line, Tumor; Diarylquinolines; Drug Delivery Systems; Dry Powder Inhalers; Ferric Compounds; Humans; Imidazoles; Lung; Magnetite Nanoparticles; Mycobacterium tuberculosis; Piperidines; Pyridines; Tuberculosis

2019
Isoniazid Bactericidal Activity Involves Electron Transport Chain Perturbation.
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:3

    Accumulating evidence suggests that the bactericidal activity of some antibiotics may not be directly initiated by target inhibition. The activity of isoniazid (INH), a key first-line bactericidal antituberculosis drug currently known to inhibit mycolic acid synthesis, becomes extremely poor under stress conditions, such as hypoxia and starvation. This suggests that the target inhibition may not fully explain the bactericidal activity of the drug. Here, we report that INH rapidly increased

    Topics: Adenosine Triphosphate; Antitubercular Agents; Cytochrome b Group; Diarylquinolines; Electron Transport; Electron Transport Chain Complex Proteins; Electron Transport Complex IV; Imidazoles; Isoniazid; Membrane Potentials; Mycobacterium bovis; Mycobacterium tuberculosis; Oxidation-Reduction; Oxygen Consumption; Piperidines; Pyridines

2019
Turning the respiratory flexibility of Mycobacterium tuberculosis against itself.
    Nature communications, 2016, 08-10, Volume: 7

    The Mycobacterium tuberculosis (Mtb) electron transport chain (ETC) has received significant attention as a drug target, however its vulnerability may be affected by its flexibility in response to disruption. Here we determine the effect of the ETC inhibitors bedaquiline, Q203 and clofazimine on the Mtb ETC, and the value of the ETC as a drug target, by measuring Mtb's respiration using extracellular flux technology. We find that Mtb's ETC rapidly reroutes around inhibition by these drugs and increases total respiration to maintain ATP levels. Rerouting is possible because Mtb rapidly switches between terminal oxidases, and, unlike eukaryotes, is not susceptible to back pressure. Increased ETC activity potentiates clofazimine's production of reactive oxygen species, causing rapid killing in vitro and in a macrophage model. Our results indicate that combination therapy targeting the ETC can be exploited to enhance killing of Mtb.

    Topics: Adenosine Triphosphate; Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Electron Transport Chain Complex Proteins; Hep G2 Cells; Humans; Imidazoles; Inhibitory Concentration 50; Macrophages; Mice; Mutation; Mycobacterium tuberculosis; Piperidines; Pyridines; RAW 264.7 Cells; Reactive Oxygen Species; Tuberculosis, Multidrug-Resistant

2016